Clinical trial · ClinicalTrials.gov
A Study of Tirzepatide for the Treatment of Obesity or Overweight in Participants Without Type 2 Diabetes
NCT04159132
Trial identity
- Registry
- ClinicalTrials.gov
- Registry ID
- NCT04159132
- Phase
- Phase 3
- Design
- Interventional
- Allocation
- Randomized
- Masking
- Double-blind
- Overall status
- Completed
- Result status
- published
Sponsors & collaborators
- Sponsor
- Eli Lilly
- Collaborators
- —
Intervention assets
Arms
| Arm | Intervention | Enrollment |
|---|---|---|
| Tirzepatide 5 mg | tirzepatide 5 mg once weekly | — |
| Tirzepatide 10 mg | tirzepatide 10 mg once weekly | — |
| Tirzepatide 15 mg | tirzepatide 15 mg once weekly | — |
| Placebo | placebo once weekly | — |
Population & enrollment
- Population summary
- Adults with obesity or overweight without diabetes.
- Eligibility summary
- BMI ≥30 or ≥27 with comorbidity; no diabetes.
- Planned enrollment
- 2539
- Actual enrollment
- 2539
Endpoints
- Primary endpoint
Percent change in body weight from baseline at week 72
- Secondary endpoints
Weight loss thresholds
Cardiometabolic parameters
Dates
- Start date
- Dec 2, 2019
- Primary completion
- Apr 1, 2022
- Completion date
- Jul 1, 2022
- Last synced
- Aug 15, 2024
Locations
- United States
- Multiple countries
Plain-language interpretation
A Study of Tirzepatide for the Treatment of Obesity or Overweight in Participants Without Type 2 Diabetes is a Phase 3 Interventional sponsored by Eli Lilly. It is evaluating Tirzepatide in Adults with obesity or overweight without diabetes.. The primary endpoint is Percent change in body weight from baseline at week 72.
Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against ClinicalTrials.gov.
Sources
- registryprimary record
SURMOUNT-4: Tirzepatide after intensive lifestyle intervention
Eli Lilly and Company · ClinicalTrials.gov · Nov 21, 2019 · NCT04159132